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Abstract
Vascular smooth muscle cells (VSMCs) are the predominant cell type in the arterial wall and normally adopt a 
quiescent, contractile phenotype to regulate vascular tone. In the arterial wall, VSMCs are exposed to multiple 
mechanical cues, including stretch and matrix stiffness, which regulate VSMC contraction. However, during ageing 
and in vascular disease, such as atherosclerosis, hypertension and vascular calcification, the arterial wall stiffens and 
VSMC contraction contributes to this process. VSMCs display remarkable plasticity and changes in their mechanical 
environment promote VSMCs to adopt a proliferative, synthetic phenotype. VSMC phenotypic modulation is associated 
with altered expression of contractile proteins that generate actomyosin-based force. However, our understanding of 
precise mechanisms whereby altered mechanical landscape and mechanotransduction influence VSMC contraction 
remains limited. In this review, we discuss the present literature describing how VSMCs sense and respond to changes 
in their mechanical environment and how these changes influence VSMC contraction.
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INTRODUCTION
Cardiovascular disease (CVD) remains one of most prevalent risk factors to health worldwide, and is the 
second highest cause of mortality within the UK[1]. The aberration of health caused from CVD places a heavy 
burden on the health-care of developing countries as well as representing a major cause of death and morbidity 
in industrialised countries[2,3]. CVD is an umbrella term, which holds host to multiple related diseases, 
including peripheral arterial disease, coronary heart disease and stroke[4]. The risk factors of each vary 
depending on the specificity of the disease, however many present common symptoms, providing a crucial 
link in treatment methods. Common physiological risk factors are hypertension, obesity, a rise in cholesterol 
and diabetes with treatment of each providing a larger scale preventative therapy of CVD[5]. Despite this, the 
largest risk factor associated with CVD is ageing, an inevitable process that all individuals undergo.
Ageing causes an increase in CVD incidence and prevalence due to wide array of changes that occurs as a 
person becomes older. The cause of ageing requires a diverse and intricate investigation into the crosstalk 
between multiple genetic and environmental (i.e., diet, exercise and smoking) factors[6]. A key modification 
observed is the structural and functional alterations within the vasculature. This includes the stiffening 
of the arteries, in particular the aorta. The function of the aorta is crucial in converting the large output 
of oxygenated blood from the left ventricle into a more controlled f low within the smaller arterioles 
and capillaries[7]. Stiffening ultimately reduces aortic compliance and increases systolic arterial pressure 
that augments the overall vascular resistance[8]. To compensate, the left ventricle adopts a compensatory 
mechanism creating a change in the end-systolic volume as well as prolonging systolic contraction. A 
direct consequence of this is the thickening of the left ventricle, which causes an aberrant hypertrophic 
physiology[9]. Coupled to this, ageing also causes defects in the repair mechanisms of the vasculature which 
further drives the diseased-phenotypic changes[10]. This, in turn, diminishes the capability of the vascular 
system to overcome the increased workload that is generated as a repercussion. Thus, ageing presents as the 
most predicative cause of CVD.
ARTERIAL STIFFNESS: CAUSE AND RELEVANCE IN CVD
Arterial stiffness is a predicative biomarker in ageing and CVD, including atherosclerosis, hypertension 
and obese populations[11-13]. Normally, pulse pressure expands the elastic arteries, transferring energy from 
the blood to the arterial wall and slowing pulse velocity. In conditions of enhanced arterial stiffness, pulse 
pressure is no longer able to expand the artery, increasing pulse velocity, and pulse pressure is transmitted 
to the microcirculation of organs such as the heart and lungs[14]. Vessels of the microcirculation are more 
fragile, resulting in damage to the microcirculation. The current gold standard method in assessing arterial 
stiffness is pulse wave velocimetry (PWV)[15]. A higher PWV is linked to individuals who have greater risk 
of CVD[16]. As a result, this method can be utilised to provide a predictive analysis of CVD independent of 
standard blood pressure measurements of the brachial artery[17].
ARTERIAL STRUCTURE
Elastic arteries, including the aorta, are structurally composed of three layers; the tunica intima is the 
innermost layer [Figure 1]. It is comprised of a sheet of endothelial cells along with a basal membrane 
and collagen fibrils. The tunica media neighbours the tunica intima as the middle layer and is primarily 
composed of vascular smooth muscle cells (VSMCs) reinforced with elastin and collagen fibrils. The final 
and outermost layer is the tunica adventitia, containing largely connective tissue as a means to provide 
reinforcement to the structure of the aorta[18]. This allows the aorta to act as an “elastic buffering chamber” 
in order to store and transmit blood to the peripheral circulation during systole and diastole, respectively[19].
This function becomes aberrant when aortic stiffness increases. Stiffness augmentation of the aorta is 
ultimately driven by changes in extracellular matrix (ECM) composition, in particular enhanced elastic 
degradation as well as augmented collagen deposition[20,21]. All three arterial layers are mechanoresponsive 
and remodel during vascular disease progression[22-24]. In this review, we focus on the response of the VSMC 
layer to enhanced matrix stiffness. Elastin in small arteries and the aorta allows for vascular distensibility 
and in normal conditions, is found in high abundance within these vessels[21]. However, this dogmatic 
view on arterial stiffness was recently found to be misleading, as an in depth analysis of the published data 
on hypertension found collagen levels to be inconsistent[25]. Due to this, several studies have now found 
multiple contributing factors towards aortic stiffness, ranging from, but not limited to, mechanical stimuli, 
inflammatory cytokines and compositional changes in the ECM[25]. The existing treatment therapies of aortic 
Page 2 of 13                                                      Ahmed et al. Vessel Plus 2018;2:36  I  http://dx.doi.org/10.20517/2574-1209.2018.51
stiffness involve different anti-hypertensive drugs, which have an indirect effect on arterial stiffness[25]. These 
drugs block calcium-channels and angiotensin II receptors, both of which modulate VSMC contraction and 
vascular tone, as opposed to ECM composition. Therefore, VSMCs have a fundamental role in the aortic 
stiffness and much of the focus has now shifted onto VSMC structure and function[26].
VSMC PHENOTYPIC MODULATION AND THE CYTOSKELETON
VSMC are the predominant cell type within the arterial wall. They are arranged in a fibrous helix and 
regulate vessel diameter and vascular tone[27]. Within a mature artery, VSMCs exist in a quiescent, 
contractile state and regulate vascular tone via vessel constriction[28]. However, VSMCs retain phenotypic 
plasticity and can dedifferentiate into a proliferative, synthetic state[29,30]. VSMC phenotypic modulation is 
associated with developmental and disease associated vessel remodeling, where VSMCs exhibit higher rates 
of proliferation, migration and altered ECM deposition[29,30].
The key filamentous components of the VSMC cytoskeleton are the intermediate filaments, microtubules 
and actin. Intermediate filaments, including vimentin and desmin, maintain VSMCs 3D structure[31]. In 
contrast, the properties of microtubules are not as clearly defined due to variable tissue types and staining 
methods. Actin filaments transmit mechanical signals to dense plaques which act as signalling hubs and 
are found dispersed within the cytoplasm[24]. Three different isoforms of actin exist, alpha, beta and gamma 
actin, with alpha actin being the abundant isoform typical within contractile VSMCs[24,32]. Changes in both 
extracellular and intracellular tension, alter actin cytoskeletal organisation and regulate cell contraction, 
migration and survival[33].
VSMC phenotypic modulation is commonly associated with altered contractile marker expression[34]. 
Contractile VSMCs possess smooth muscle myosin II (SM-myosin II), smoothelin and smooth muscle-
actin and these are downregulated in models where arterial injury[35]. SM-myosin II is the dominant myosin 
isoform found within contractile VSMC and is composed of both two heavy and light chains. There are 
two different types of light chains identified as myosin light chain-20 (MLC-20) and MLC-17, with the 
phosphorylation of the former regulating VSMC contraction[36]. In contrast, synthetic VSMCs contain non-
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Figure 1. Schematic representation of arterial structural organisation
muscle myosin II (NM-myosin II), which is upregulated in the proliferative state[35]. NM-myosin II is also 
expressed in the differentiated state, albeit at lower levels. Once phosphorylated, myosin associates with 
actin filaments to form the actomyosin complex. The ATPase activity of the myosin then results in rapid 
cycling of the cross-bridges formed between actin and myosin, thus causing a pulling of the actin thin 
filaments[36]. The physiological function of the two myosin isoforms vary and the SM-myosin II has a higher 
immune-reactivity in tissue areas where faster phasic VSMC contractions were occurring[37]. This is in 
contrast to NM-myosin II, which primarily regulates the slower tonic phase of VSMC contraction[37]. The 
tonic contraction induced from NM-myosin II generates less force than phasic contraction produced from 
SM-myosin II[37,38].
VSMC CONTRACTION
Calcium-dependent pathway
VSMC contraction occurs via two interlinked pathways that contribute synergistically to the contractile 
properties of VSMCs [Figure 2]. The first pathway, more commonly known as the calcium-dependent 
pathway, primarily involves augmenting cytoplasmic calcium levels to induce phasic contraction. Increased 
intracellular calcium can be triggered by mechanical, electrical and chemical stimuli, either by calcium 
influx from channels located on the plasma membrane or by release of calcium from the sarcoplasmic 
reticulum (SR)[39]. Calcium entry from the extracellular space usually occurs via voltage gated calcium 
channels (VGCCs) or non-selective cation channels. Sub-populations of L-type, P/Q-type and T-type 
VGCCs are all found within VSMCs and are activated via depolarization[40]. In addition, non-selective cation 
channels, found to predominantly be members of the transient receptor potential canonical family, allow for 
Na+ and Ca2+ influx following receptor occupancy or capicitative calcium entry[40].
Release of calcium from the SR is predominantly mediated by the activation of G-protein coupled receptors 
(GPCRs) (i.e., the AT1 receptor) coupled to the Gaq G-protein. The Gaq protein, when in its GTP-bound 
state, causes activation of phospholipase C which hydrolyses phosphatidylinositol 4,5-bisphosphate 
(PIP2) into inositol triphosphate (IP3) and diacylglycerol[41,42]. IP3 binds to the IP3 receptors present on 
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Figure 2. Calcium dependent and independent regulation of VSMC contraction. The two pathways work synergistically. Calcium 
dependent regulation is associated with transient phasic contraction whereas RhoA/ROCK regulation is associated with the prolonged 
tonic contraction of VSMCs. GPCR: G-protein coupled receptor; IP3: inositol triphosphate; SR: sarcoplasmic reticulum; Rho GEF: 
RhoGTPase guanine nucleotide exchange factors; ROCK: Rho-associated protein kinase; MLC: myosin light chain; VSMC: vascular 
smooth muscle cell
the sarcolemma, which causes opening of the calcium channels and subsequent depletion of calcium 
intracellular store.
After an increase of cytoplasmic calcium concentration has been established, calmodulin becomes bound by 
4 calcium ions. The resulting calcium-calmodulin complex interacts with and activates myosin light chain 
kinase (MLCK)[43]. Next, MLCK phosphorylates MLC-20 (also known as the regulatory light chain) on the 
serine-19 and threonine-18 residues. The phosphorylation of serine-19 causes a resulting increase in the 
activity of the Mg2+-ATPase and this effect is further enhanced by the phosphorylation of the latter residue. 
From this, the cross-bridge cycling is initiated and the myosin head can actively pull on the thin filament of 
the actin to induce contraction of the muscle[44].
Rho/Rho-associated protein kinase pathway
In the absence of external contractile stimuli, the MLC-20 light chain remains phosphorylated at a low level. 
This low level leads to a slower tonic form of contraction, which regulates the vascular tone[36]. A calcium-
independent pathway that involves Rho/Rho-associated protein kinase (ROCK) signalling regulates VSMC 
tonic contractions [Figure 2]. This pathway not only caters to contractile function, but also extends to 
smooth muscle cell migration, proliferation and apoptosis[45]. RhoA, part of the Ras superfamily, is a GTPase 
which can act as a molecular switch between a GTP/GDP bound state[46]. In resting conditions, the Rho GDP 
dissociation inhibitor targets GDP-Rho for binding, as a means to localise the GTPase from the membrane 
to the cytosol. However, activation of GPCR receptors, in particular Ga12/13 subtypes, can catalyse GTP for 
GDP exchange in RhoA by binding to p115 RhoGTPase guanine nucleotide exchange factors[47]. In its GTP 
bound form, RhoA can interact with target proteins by utilising its C-terminal geranyl-geranylated tail to 
anchor itself to the plasma membrane[47].
One of the target proteins activated by RhoA is ROCK[48]. ROCK is a member of the protein kinase A, G 
and C family of protein kinases, and is characterised as a serine/threonine kinase. There are two isoforms 
of this kinase, referred to as ROCK1 and ROCK2, with expression of both present in VSMCs[49]. Its 
structure is composed of an N-terminal kinase domain, a central coiled-coil domain and a C-terminal 
pleckstrin homology domain that associates with the Rho GTPase[47]. ROCK has many effects within 
VSMCs and inf luences actomyosin activity by two main pathways. Firstly, ROCK actively regulates 
cytoskeletal organisation by preventing actin filament depolymerisation[48]. Secondly, ROCK inhibits 
myosin light chain phosphatase (MLCP). MLCP has a structure that is composed of three subunits; a 37 
kDa catalytic subunit, a variable subunit and a myosin-binding subunit[36]. The myosin-binding site is 
crucial for its regulation and is subject to phosphorylation, specifically at residues. Threonine-695/697 (major 
site), serine-849/854 and threonine-850/855[47,50]. Phosphorylation prevents MLCP from regulating the MLC 
phosphorylation state and increases the basal phosphorylated MLC level, stimulating VSMC contraction 
and augmenting vascular tone[50].
 
MEMBRANE ANCHORS TO THE ACTIN CYTOSKELETON
VSMCs make connective junctions to their surrounding environment, which includes the ECM and 
neighboring cells within the vasculature. These adhesions play a vital role in determining morphology 
and VSMC function. The adhesion molecules that are utilised by VSMCs can be separated, despite their 
structural and functional similarities[51].
Cell-cell adhesions
Cadherins are the primary molecules in cell-cell adhesion formation. The most abundant isoforms are E 
(epithelial)-, P (placental)- and N (neuronal)-cadherins, all of which belong to the type I classical cadherin 
family[52,53]. N-cadherin is the predominant cadherin in VSMCs and mediates cell-cell adhesion formation 
with neighbouring endothelial cells as well as other VSMCs[53]. The N-cadherin adhesion plays important roles 
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in regulating VSMC function. N-cadherin adhesions suppress both VSMC proliferation and apoptosis[54,55]. 
N-cadherin is also involved in VSMC migration; however, its exact role currently remains unclarified[56].
N-cadherin is composed of a large extracellular N-terminal domain, flanked by a single trans-membrane 
anchoring domain and a small cytoplasmic tail[52]. The large extracellular domain consists of five cadherin 
(EC) repeat regions that are important in coupling N-cadherin into a parallel homodimer via linkage 
between adjacent EC repeats[52,53]. EC repeats require calcium binding which stabilises the interaction 
between the parallel cadherin molecules[56,57]. The cadherin homodimer of one cell interacts with the 
homodimer of an adjacent cell by interchanging a specific beta strand, referred to as the A* strand, found 
in the EC1 domain[58]. This interaction, referred to as trans-binding, is necessary for the formation of cell-
cell adhesions[53]. The cytoplasmic tail of N-cadherin is linked to the actin cytoskeleton via a number of 
cytoskeleton-associated proteins, including β-catenin, p120-catenin and α-catenin. α-catenin is recruited to 
the adhesion structure via β-catenin and plays a crucial role in providing a link between the N-cadherin-based 
junction and the actin cytoskeleton[59].
Cadherin-based mechanotransduction is observed in multiple cell types and induces adhesion and 
cytoskeletal remodelling, altered adhesion strength and changes in actomyosin activity. Evidence suggests 
that N-cadherin-based adhesions are important for VSMC contraction and mechanotransduction; β-catenin 
recruitment to N-cadherin-based adhesions is necessary for VSMC contraction, and N-cadherin is essential 
for VSMC myogenic response to changes in pressure. Despite this evidence, our understanding of the role of 
N-cadherin-based mechanotransduction in VSMC function remains poorly defined.
Cell-matrix adhesions
Cell-matrix adhesions possess integrin receptors at their core[60]. Integrins span the plasma membrane and 
physically associate with different ECM components[61]. Integrin receptors perform both structural and 
mechanosensing signalling functions within cell-matrix adhesions. Integrins form heterodimers, consisting 
of an alpha and beta subunit[62] and are structurally comprised of an extracellular ligand-binding domain, 
which binds the ECM, and a cytosolic domain, which is anchored to the actin cytoskeleton[63]. Before 
transducing intracellular tension to the ECM, the integrin receptors must mature via the recruitment of 
further integrin receptors as well as other cytoskeletal components[64]. Talin and alpha-actinin bind directly 
to the cytosolic domain of integrin and talin binding promotes the recruitment of additional components 
to cell matrix adhesions, including vinculin, paxillin and focal adhesion kinase[62,65]. Vinculin consists of 
3-stuctural regions known as the head, neck and tail domain[66]. The vinculin binding site is auto-inhibited 
by interactions between its head and tail domain[66]. This interaction is disrupted by talin/alpha actinin, via 
individual binding or cooperatively with PIP2[67]. Once disrupted, the activated form can then associate with 
cell-matrix adhesions via talin[67]. Physical stress induces exposure of vinculin binding sites on talin’s rod 
domain allowing vinculin binding. In addition, the vinculin molecule also associates with actin filaments, 
thereby crosslinking the actin cytoskeleton to the integrin receptors. This allows force transduction from the 
contractile machinery of VSMCs to be transmitted to the ECM[66].
The linker of nucleoskeleton and cytoskeleton complex
The nuclear envelope (NE) is a double lipid bilayer that consists of an outer nuclear membrane (ONM) and 
an inner nuclear membrane (INM), separated by a perinuclear space [Figure 3]. The ONM and INM are 
continuous and join at nuclear pores[68]. A meshwork of A-type and B-type lamin intermediate proteins 
and lamina associated proteins, collectively known as the nuclear lamina, underlies the INM and provides 
structural support to the NE[68]. The linker of nucleoskeleton and cytoskeleton (LINC) complex, comprised 
of nesprin-family members and SUN-domain containing proteins, spans the NE. Giant nesprin-1/2 
isoforms reside on the ONM and associate with filamentous actin via N-terminal calponin homology 
(CH) domains[69]. Within the perinuclear space, binding of the nesprin Klarsicht, Anc-1, Syne-1 homology-
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domain to the SUN-domain of SUN1/2 maintains LINC complex stability[70,71]. At the INM, SUN1/2 interact 
with lamins A/C[71], allowing the plasma membrane and nucleus to function as a mechanically coupled 
system [Figure 3].
The LINC complex is a regulator of cytoskeletal organisation and directly transmits biophysical signals 
into the nucleus. The LINC complex is subjected to mechanical tension and actomyosin-generated forces 
are directly transduced across the NE to the nuclear lamina[72,73]. However, the LINC complex exists in 
mechanical balance with mechanotransduction and LINC disruption triggers cell-matrix adhesion, cell-
cell adhesion and cytoskeletal reorganisation[74,75]. LINC complex disruption also alters actomyosin activity, 
nesprin disruption enhances actomyosin activity in skeletal muscle progenitor and endothelial cells, whereas 
lamin A disruption in skeletal muscle progenitor cells enhanced actomyosin activity and reduced actomyosin 
activity in fibroblast cells[76,77]. This suggests that the LINC complex plays cell-specific roles in regulating 
actomyosin activity and disruption of the nuclear lamin A during ageing alters VSMC morphology and cell-
matrix organisation[78]. However, the role of the LINC complex in VSMC actomyosin regulation remains 
unknown. Although the mechanism of this LINC complex/actomyosin feedback remains unknown, lamin 
A/C and SUN2 regulate Rac1 and RhoA activity, respectively[78,79].
MECHANOTRANSDUCTION AND THE ECM
Sensing the extracellular environment
Extracellular mechanical cues directly regulate VSMC function, including actomyosin activity, 
adhesion, differentiation and migration[66]. To achieve this, VSMCs must convert mechanical signals into 
biochemical response via a process known as mechanotransduction. Mechanosensors range from stretch-
sensitive channels, cytoskeletal filaments, cytosolic proteins and nuclear proteins, all of which undergo 
conformational changes when encountering intra/extracellular tension[80].
Conformational changes induced by tension alters mechanosensors modification, interactions and 
localisation within the cell[81]. Vinculin, in particular, acts as a regulator of mechanical stress in addition 
to its role as a mechano-coupler. As a result, cells regulate their function by actively exerting and resisting 
forces both to and from the ECM as a means to adjust their mechanical properties[82]. Force is transmitted 
via cell-matrix adhesions, which serve as bidirectional signalling conduits, enabling “inside-out” and 
“outside-in” signalling[82]. This is crucial for the maintenance of normal physiology as well as injury-repair, 
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Figure 3. Schematic representation of adhesion organisation and the LINC complex in VSMCs. ONM: outer nuclear membrane; INM: 
inner nuclear membrane; ECM: extracellular matrix; LINC: linker of nucleoskeleton and cytoskeleton; VSMC: vascular smooth muscle cell
by offsetting signalling pathways that induce appropriate gene expression. Due to this, the cell can enable 
structural remodelling of the cytoskeleton, which allows for correct adjustment of the vascular tone and in 
turn the blood flow[24].
Mechanotransduction: role of stretch
The cyclical process of the cardiac pumping creates numerous mechanical stimuli, all of which the vascular 
smooth muscle is exposed to. Examples are transmural pressure, circumferential wall tension and vascular 
shear strain[24]. Shear stress predominantly acts on the tunica intima, where endothelial cells reside. In the 
tunica media, VSMCs are subjected to cyclic stretch that originates from the pulsatile blood pressure[27]. 
Pulsatile stretch is cyclical in nature due to a rise in blood flow during the systolic phase and then a gradual 
decrease when in the diastolic phase[83]. This form of pressure induces rapid cell-matrix and actin filament 
reorganisation[24]. Stretch also physically opens mechanically gated cation channels, promoting Ca2+ ion entry 
and VSMC contraction[84,85]. Stretch signals also regulate activity of several important signalling molecules, 
including protein kinase C and Akt. Therefore stretch signals regulate a range of VSMC functions, including 
proliferation, migration and apoptosis[27].
CVD and the role of matrix stiffness
VSMCs can sense the stiffness of their surrounding matrix and respond by exerting actomyosin-generated 
tension on the ECM. As the stiffness of a material increases, its elasticity decreases[86]. Therefore, as matrix 
stiffness is augmented, vessel stretch signals decrease and there is a switch from transient stretch signals 
to sustained stiffness signalling. Decreased arterial compliance is commonly found in the early stages of 
numerous CVDs such as atherosclerosis, restenosis and aneurism. Atherosclerosis is an inf lammatory 
CVD that acts as the underlying cause of heart attack, stroke and cardiac death[87]. The development of this 
disease primarily involves the endothelial intimal layer and the vascular smooth muscle medial layer[88] 
and results in the formation of an atherosclerotic plaque, containing a lipid core surrounded by a fibrous 
cap. Atherosclerosis decreases aortic compliance and the stiffness of the individual components of an 
atherosclerotic plaque has been measured by atomic force microscopy, which displays a range of stiffness, 
from the soft lipid core (~5 kPa), to the relatively healthy cellular regions (~10 kPa), to the stiff fibrous cap 
(60-250 kPa)[89].
VSMC phenotypic modulation, proliferation and migration is prevalent in atherosclerosis and there is a 
clear coloration between changes in arterial compliance and atherosclerotic disease progression[11,90]. Yet our 
understanding of the influence of matrix stiffness on VSMC function remains limited. VSMCs exposed to 
enhanced matrix stiffness display increased intracellular tension and form larger cell-matrix adhesions[25,91]. 
VSMC stiffness is also augmented in hypertension and diabetes[25,26]. Importantly, treatment with actin 
inhibitors reduce VSMCs stiffness, suggesting that the stiffer aortic environments increase actomyosin force 
generation in VSMCs[26].
In addition to altered actomyosin activity, matrix stiffness also potentially influences VSMC differentiation. 
VSMC phenotype is regulated by numerous environmental cues, including the ECM[92]. Atherosclerotic 
plaques display reduced levels of elastin and collagen-I accumulation[93]. Fetal aortic VSMCs display 
enhanced traction forces and actomyosin activity when matrix stiffness is increased from 10 kPa to 25 kPa[93]. 
However, they fail to produce sufficient force to displace a 135 kPa matrix[93], suggesting that VSMCs lose the 
ability to contract and deform their surrounding ECM under enhanced matrix stiffness. In agreement with 
this notion, VSMCs lose the ability to contract and deform the ECM when surrounded by stiff collagen-I 
fibrils in 3D models[94]. In stiff environments, VSMCs exert higher levels of mechanical tension, which 
directs a proliferative change to the synthetic phenotype[94]. Expression levels of key contractile marker 
proteins, such as alpha smooth muscle actin, are reduced when collagen-I gel concentration is increased[92]. 
Furthermore, VSMCs transition to the synthetic state when stiffness and nanotopography of the substrate is 
increased[95]. Therefore, ECM stiffness influences VSMC phenotypic modulation.
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As described above, matrix stiffness influences both the expression of VSMC contractile proteins and the 
ability of VSMCs to physically contract and deform their surrounding ECM. Therefore, stiffened ECM is 
no longer remodeled by the intrinsic actomyosin activity of the VSMCs[96]. However, this does not explain 
whether the absence of substrate deformation is due to a decline in VSMC actomyosin response or because 
the ECM has become too stiff to be manipulated. For example, a recent study investigated the ex-vivo vaso-
constrictor response of young and old soleus muscle feed arteries. Despite an upregulation of ROCK activ-
ity, there was a decreased constrictor response in the aged vessels[96]. Aged VSMCs were incapable of gen-
erating sufficient force to induce matrix remodeling[96]. However, ECM deformation was used to assess the 
vasoconstrictor response and given that aged arteries are stiffer than their younger counterparts, VSMC 
actomyosin activity may remain intact[97]. In agreement with this, cell-matrix adhesions were subjected to 
increased mechanical load in aged arteries, compared to their younger counterparts[96]. Further investiga-
tion is now required to assess whether the mechanisms of VSMC actomyosin signaling is influenced by 
matrix stiffness.
Finally, directional cellular migration is also induced by gradients of ECM stiffness, known as durotaxis. Du-
rotaxis contrasts from chemotaxis and haptotaxis due to an absence of soluble chemical signals or adhesive 
ligand density, respectively[98]. Both healthy and diseased tissues possess heterogeneity in their mechanical 
stiffness indicating the presence of gradients[89,99-102]. VSMC directional migration is prevalent in atheroscle-
rosis and VSMCs are exposed to low (~5 kPa) and high matrix stiffness (> 200 kPa) within the atherosclerotic 
plaque. VSMCs orientate in the direction of an ECM stiffness gradient[98] and show a directed migration 
towards a mechanical gradient when plated on gels coated with fibronectin as opposed to laminin[103]. Fibro-
nectin is found in high concentrations in atherosclerotic lesions, suggesting that ECM composition is a key 
component of VMSC durotaxis. It remains unknown whether durotaxis, chemotaxis and haptotaxis work co-
operatively to regulate VSMC migration in atherosclerosis, however, matrix stiffness gradients may participate 
in the enhanced VSMC migration observed in vascular diseases such as atherosclerosis.
CONCLUSION
Evidence clearly dictates that matrix stiffness plays a crucial role in CVD. However, its effects on VSMCs, 
the predominant cell type within the aorta, remains poorly defined. The majority of VSMC research has 
been performed on tissue culture plastic or glass, which are over 1000 times stiffer than an arterial wall. 
There is a pressing need to utilise materials that more closely replicate both physiological and pathological 
stiffness in VSMC research. Several important questions remained unanswered: (1) the signalling pathways 
regulating VSMC function in response to matrix stiffness remain to be fully elucidated; (2) do VSMCs from 
different vascular beds possess unique force generating capabilities in response to matrix stiffness; and (3) 
how do other cell types, including endothelial cells, tune VSMC actomyosin activity in response to matrix 
stiffness? Answering these questions will facilitate an understanding of the aetiology of arterial stiffness on 
VSMC function that will potentially allow development of new therapeutic avenues for the treatment of a 
wide range of CVDs.
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